Feel Comfortable Sticking With NovoSeven RT Over Sevenfact
December 2020
Sevenfact will join NovoSeven RT as another recombinant factor VIIa option to control bleeding in certain patients with hemophilia.
Sevenfact is currently approved to treat bleeds of any severity in patients 12 years and up with hemophilia A or B who develop “inhibitors”...antibodies to factor replacements.
Inhibitors can form against factor VIII (Advate, etc) or IX (BeneFix, etc) products...which limit their use to treat bleeding.Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote